Safety Alerts & Recalls
What does this mean?
The FDAï¿½(tm)s recent evaluation confirmed that serious reports of tendinitis and tendon rupture with the fluoroquinolones, like moxifloxacin (Avelox), continue to be reported. The risk of tendinitis and tendon rupture is further increased in those over age 60, in kidney, heart, and lung transplant recipients, and with use of concomitant steroid therapy.
Most patients who are prescribed fluoroquinolones tolerate these medicines without serious side effects. That said, you should (1) be aware of the possibility of tendinitis and tendon rupture, (2) regularly balance the benefits and risks of treatment with your doctor, and (3) immediately contact your doctor and avoid exercise and joint use if you experience any signs of tendon pain, swelling, or inflammation.
Increased risk of tendinitis and tendon rupture
The U.S. Food and Drug Administration (FDA) notified healthcare professionals that a boxed warning is to be added to the prescribing information about the increased risk of developing tendinitis and tendon rupture in patients taking fluoroquinolone antimicrobial drugs, like moxifloxacin (Avelox) for systemic use.
For more information, please visit: more information here